FDA Grants Orphan Drug Designation To OSE's Pegrizeprument For Post-Heart Transplant Rejection

OSE Therapeutics said the FDA granted orphan drug designation to pegrizeprument for prophylaxis of heart allograft rejection after heart transplant. The designation is a positive regulatory milestone for the clinical-stage biotech, but it does not constitute approval or commercial revenue. Market impact is likely limited unless followed by additional clinical or regulatory progress.

Analysis

OSE Therapeutics said the FDA granted orphan drug designation to pegrizeprument for prophylaxis of heart allograft rejection after heart transplant. The designation is a positive regulatory milestone for the clinical-stage biotech, but it does not constitute approval or commercial revenue. Market impact is likely limited unless followed by additional clinical or regulatory progress.